ArticleFrontiers in medicine2026
Clinical outcomes of residual branch vessel dissection following type A aortic dissection repair.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Although aortic arch replacement eliminates the primary entry tear in type A aortic dissection, residual dissection in arch branch vessels (RD-ABV), often linked to fragile distal tissue or residual tears, may sustain false lumen patency and be related to post-discharge recovery. The clinical relevance of RD-ABV remains unclear. Methods: This retrospective cohort study included patients who underwent total arch replacement for aortic dissection between January 2018 and December 2024. Patients with in-hospital postoperative cerebral infarction, cerebral hemorrhage, or death were excluded, and follow-up began on the date of discharge. RD-ABV was assessed using the first postoperative CTA before discharge. The primary outcome was a composite event including modified Rankin Scale (mRS) 3-6, cerebral infarction (CI), cerebral hemorrhage (CH), and cardiovascular and cerebrovascular reoperation. Secondary outcomes included CI, CH, and reoperation. IPTW-adjusted win ratio was used for analyses of the primary and secondary composite outcomes. Results: A total of 564 patients were included, of whom 156 had RD-ABV. The IPTW-adjusted win ratio of the primary composite outcome was 0.47 (95% CI: 0.27-0.82; Conclusion: Among selected post-discharge survivors after aortic arch replacement, RD-ABV was associated with worse mid-term functional recovery, mainly reflected by mRS 3-6. The secondary composite outcome excluding mRS did not reach statistical significance. These findings should be interpreted as hypothesis-generating and require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.